Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Zimerman

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
ESC Heart Failure|February 10, 2025
Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fractionSilas Ramos Furquim, Edimar Alcides Bocchi, Maria Tereza Sampaio de Sousa Lira, et al.
European Journal of Preventive Cardiology|October 28, 2025
Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic DiseaseAndre Zimerman, Frederick K Kamanu, Giorgio E M Melloni, et al.
Journal of the American College of Cardiology|August 6, 2025
Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF SubstudyAndre M Nicolau, Robert P Giugliano, Andre Zimerman, et al.
Circulation|March 30, 2026
Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging StudyNicholas A Marston, Brian A Bergmark, Thomas A Prohaska, et al.
The New England Journal of Medicine|November 10, 2025
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis RiskNicholas A Marston, Brian A Bergmark, Veronica J Alexander, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
ESC Heart Failure|February 10, 2025
Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fractionSilas Ramos Furquim, Edimar Alcides Bocchi, Maria Tereza Sampaio de Sousa Lira, et al.
European Journal of Preventive Cardiology|October 28, 2025
Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic DiseaseAndre Zimerman, Frederick K Kamanu, Giorgio E M Melloni, et al.
Journal of the American College of Cardiology|August 6, 2025
Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF SubstudyAndre M Nicolau, Robert P Giugliano, Andre Zimerman, et al.
Circulation|March 30, 2026
Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging StudyNicholas A Marston, Brian A Bergmark, Thomas A Prohaska, et al.
The New England Journal of Medicine|November 10, 2025
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis RiskNicholas A Marston, Brian A Bergmark, Veronica J Alexander, et al.
Pageof 2